Topoisomerase 1 inhibition therapy protects against SARS-CoV-2-induced inflammation and death in animal models.
Ho, J. S. Y.; Mok, B. W.-Y.; Campisi, L.; Jordan, T.; Yildiz, S.; Parameswaran, S.; Wayman, J. A.; Gaudreault, N. N.; Meekins, D. A.; Indran, S. V.; Morozov, I.; Trujillo, J. D.; Fstkchyan, Y. S.; Rathnasinghe, R.; Zhu, Z.; Zheng, S.; Zhao, N.; White, K.; Ray-Jones, H.; Malysheva, V.; Thiecke, M. J.; Lau, S.-Y.; Liu, H.; Zhang, A. J.; Lee, A. C.-Y.; Liu, W.-C.; Aydillo, T.; Melo, B. S.; Guccione, E.; Sebra, R.; Shum, E.; Bakker, J.; Kaufman, D. A.; Moreira, A.; Carossino, M.; Balasuriya, U. B. R.; Byun, M.; Miraldi, E. R.; Albrecht, R. A.; Schotsaert, M.; Garcia-Sastre, A.; Chanda, S. K.; Jeya
Show abstract
The ongoing pandemic caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is currently affecting millions of lives worldwide. Large retrospective studies indicate that an elevated level of inflammatory cytokines and pro-inflammatory factors are associated with both increased disease severity and mortality. Here, using multidimensional epigenetic, transcriptional, in vitro and in vivo analyses, we report that Topoisomerase 1 (Top1) inhibition suppresses lethal inflammation induced by SARS-CoV-2. Therapeutic treatment with two doses of Topotecan (TPT), a FDA-approved Top1 inhibitor, suppresses infection-induced inflammation in hamsters. TPT treatment as late as four days post-infection reduces morbidity and rescues mortality in a transgenic mouse model. These results support the potential of Top1 inhibition as an effective host-directed therapy against severe SARS-CoV-2 infection. TPT and its derivatives are inexpensive clinical-grade inhibitors available in most countries. Clinical trials are needed to evaluate the efficacy of repurposing Top1 inhibitors for COVID-19 in humans.
Matching journals
The top 5 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Transcription regulation of SARS-CoV-2 receptor ACE2 by Sp1: a potential therapeutic target 94%
- ACE2 is the critical in vivo receptor for SARS-CoV-2 in a novel COVID-19 mouse model with TNF- and IFNγ-driven immunopathology 94%
- PIMT suppresses endothelial activation and vascular inflammation through methylation of TRAF6 94%
Similar papers in this journal
Similar papers in this journal
- Oral Hsp90 inhibitor, SNX-5422, attenuates SARS-CoV-2 replication and dampens inflammation in airway cells. 96%
- The circadian clock component BMAL1 regulates SARS-CoV-2 entry and replication in lung epithelial cells 94%
- Experimental and natural evidence of SARS-CoV-2 infection-induced activation of type I interferon responses 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.